Synopsis: Aptus Pharma announced a 3:2 bonus share issue with a May 12, 2026, record date. The company reported strong revenue and profit growth, showing solid financial performance and expansion.
This Micro-cap Pharma Stock, engaged in marketing and distribution of pharmaceutical products, offering a wide range of medicines across multiple therapeutic segments, jumped 2.64 percent after the company reported strong March 2026 results and set a record date for a 3:2 bonus issue.
With a market capitalization of Rs. 253.82 crores, the share of Aptus Pharma Limited has reached an intraday high of Rs. 370 per equity share, rising nearly 2.64 percent from its previous day’s close price of Rs. 360.50. Since then, the stock has retreated and is currently trading at Rs. 369.50 per equity share.
Reason Behind the Surge
Aptus Pharma Limited’s Board of Directors has fixed Tuesday, May 12, 2026, as the Record Date for determining the eligibility of shareholders for the allotment of Bonus Equity Shares.
The board has decided to issue bonus shares at a ratio of 3:2, meaning that shareholders will receive three new fully paid-up equity shares of Rs. 10 each for every two existing fully paid-up equity shares they hold.
For example, if a shareholder owns 1,000 shares of Aptus Pharma Limited, they will receive 1,500 bonus shares, bringing their total holding to 2,500 shares after the 3:2 bonus issue.
H2 FY26 Result Walkthrough
Coming into the half-yearly results of Aptus Pharma Limited, the company’s consolidated revenue from operations increased by 117.57 percent YOY, from Rs. 14.80 crore in H2 FY25 to Rs. 32.20 crore in H2 FY26, and grew by 123.92 percent QoQ from Rs. 14.38 crore in H1 FY26.
In H2 FY26, Aptus Pharma Limited’s consolidated net profit increased by 60.34 percent YOY, reaching Rs. 2.87 crore compared to Rs. 1.79 crore during the same period last year. As compared to H1 FY26, the net profit has increased by 64 percent, from Rs. 1.75 crore. The basic earnings per share increased by 16.76 percent and stood at Rs. 4.18 as against Rs. 3.58 recorded in the same period in the previous year, FY2025.
Annual Performance of FY26
Aptus Pharma Limited’s revenue has increased from Rs. 24.56 crore in FY25 to Rs. 46.57 crore in FY26, which has grown by 89.62 percent. The net profit has also grown by 49.03 percent from Rs. 3.10 crore in FY25 to Rs. 4.62 crore in FY26. The annual basic earnings per share increased by 8.55 percent and stood at Rs. 6.73 as against Rs. 6.20 recorded in the financial year 2025.
Aptus Pharma Limited’s revenue and net profit have grown at a CAGR of 49.63 percent and 189.71 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 30 percent and 30.5 percent, respectively. Aptus Pharma Limited’s debt-to-equity ratio is 0.31x.
Future Outlook
Aptus Pharma Limited aims to grow strongly between 2026 and 2030 by expanding its product range and market reach. The company plans to launch more than 450 products across more than 25 therapeutic segments, helping it serve a wider range of healthcare needs. It also focuses on both horizontal and vertical expansion to build a strong presence across India.
The company plans to introduce a franchise model in Odisha with the support of local C&F partners. It will also expand into nearby states like Goa, Rajasthan, Madhya Pradesh, Maharashtra, Mumbai, and Chhattisgarh within the next three years. In addition, Aptus Pharma Limited aims to enter global markets, especially in unregulated and semi-regulated regions, to grow its international presence.
Company Overview
Aptus Pharma Limited focuses on marketing and distributing finished pharmaceutical products. It does not own manufacturing plants but works with trusted partners through contract manufacturing. The company handles more than 50,000 prescriptions every day and serves over 15 therapeutic segments.
It offers a wide range of medicines, including treatments for infections, digestion, allergies, respiratory issues, nutrition, pain relief, heart health, diabetes, and general wellness. With a large central warehouse and a strong network of over 10,000 trusted doctors, the company ensures smooth supply and wide access to healthcare products.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post 3:2 Bonus Share: Pharma Stock jumps 3% After Board Sets Record Date for Bonus Issue appeared first on Trade Brains.